Richard G. Vincent - 13 Apr 2023 Form 4 Insider Report for Oncternal Therapeutics, Inc.

Role
Chief Financial Officer
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
13 Apr 2023
Net transactions value
+$8,961
Form type
4
Filing time
14 Apr 2023, 06:00:10 UTC
Previous filing
23 Feb 2023
Next filing
05 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Purchase $8,961 +30,000 +24% $0.2987 156,859 13 Apr 2023 Direct F1
holding ONCT Common Stock 4,526 13 Apr 2023 By Family Trust
holding ONCT Common Stock 1,834 13 Apr 2023 By Child
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $0.2975 to $0.3000. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares purchased at each price within the range set forth above.